Lenuxin

Escitalopram, the active ingredient in Lenuxin, is a selective serotonin reuptake inhibitor (SSRI) presented as an oral dosage form for oral use. It is prescribed for major depressive disorder and several anxiety‑related conditions in adults.

GNH USA supplies Lenuxin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Escitalopram acts on serotonergic pathways and is indicated for several mood and anxiety disorders. - Major depressive disorder: alleviates depressive symptoms and improves mood. - Generalized anxiety disorder: reduces excessive worry and tension. - Panic disorder: decreases frequency and severity of panic attacks. - Social anxiety disorder: lessens fear of social situations and improves functional performance.

Escitalopram may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient tension‑type headaches. - Insomnia: difficulty falling or staying asleep. - Dry mouth: reduced salivation causing discomfort.

Serious or Rare Side Effects: - Serotonin syndrome: potentially life‑threatening condition with agitation, hyperthermia, and neuromuscular abnormalities. - Suicidal thoughts: emergence of suicidal ideation, especially in young adults. - Severe allergic reaction: rash, swelling, or anaphylaxis requiring immediate medical attention.

Before initiating therapy, clinicians should consider several safety measures. - Assess psychiatric history: evaluate for prior depression or suicidal behavior. - Monitor for suicidality: especially during the first weeks of treatment or dose changes. - Avoid MAOI co‑administration: maintain a minimum 14‑day washout period. - Adjust in hepatic impairment: consider lower starting doses in patients with liver dysfunction. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Escitalopram can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Pimozide: may cause cardiac arrhythmias. - Thioridazine: increased QT prolongation risk. - Linezolid: additive serotonergic effects. - Other serotonergic agents (e.g., tramadol, triptans): heightened serotonin toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs and anticoagulants: increased bleeding tendency. - CYP2C19 inhibitors (e.g., fluconazole): may raise escitalopram plasma levels. - Alcohol: can exacerbate CNS depression and impair judgment.